<p>Prolyl hydroxylase domain proteins: Localization, regulation, function and their role in erythropoiesis (Review)</p>. [PDF]
Mol Med RepHou Y +5 more
europepmc +1 more source
Concerns from bench and insights from bedside: the puzzle of Roxadustat in cancer patients with chemotherapy-induced anemia. [PDF]
Front PharmacolChen L, Liao S, Jing D, Mao L, Tan J.
europepmc +1 more source
Iron-ing Out the Role of Transferrin Receptor in Kidney Development. [PDF]
Kidney360Gewin LS, Romero MF.
europepmc +1 more source
Roxadustat: A catalyst for diabetic wound healing through re-epithelialization and angiogenesis. [PDF]
CytojournalTang D, Lin Q, Xu K, Lu QP.
europepmc +1 more source
The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes. [PDF]
BMC NephrolLi C +5 more
europepmc +1 more source
Roxadustat for the Treatment of Early Post-Transplantation Anemia. [PDF]
Transpl IntGuenal L +9 more
europepmc +1 more source
Treatment of pure red cell aplasia in a chronic kidney disease patient with roxadustat: A case report. [PDF]
Open Life SciLiu S, Yan B, He Y.
europepmc +1 more source
Roxadustat for CKD-related Anemia in Non-dialysis Patients [PDF]
Kidney International Reports, 2021 Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and tolerability of roxadustat in patients with chronic kidney disease (CKD ...
Daniel W Coyne +2 more
exaly +4 more sources
Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
Journal of Clinical Medicine, 2023 Roxadustat is a novel agent with a distinct mechanism of action compared to erythropoiesis-stimulating agents (ESAs) and a potentially different combination of effects on iron parameters.
Tomas Ganz +2 more
exaly +2 more sources